Biology of Blood and Marrow Transplantation
Volume 15, Issue 9 , Pages 1130-1133 , September 2009

Toll-Like Receptor 4 Polymorphisms and Risk of Gram-Negative Bacteremia after Allogeneic Stem Cell Transplantation. A Prospective Pilot Study

  • Mensah Nana Yaa

      Affiliations

    • Department of Medicine, Service of Infectious Disease, Memorial Sloan-Kettering Cancer Center, New York, New York
    • ,
  • Peterlongo Paolo

      Affiliations

    • Cell Biology Program, Memorial Sloan-Kettering Cancer Center, New York, New York
    • ,
  • Steinherz Peter

      Affiliations

    • Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York
    • ,
  • Pamer G. Eric

      Affiliations

    • Department of Medicine, Service of Infectious Disease, Memorial Sloan-Kettering Cancer Center, New York, New York
    • ,
  • Satagopan Jaya

      Affiliations

    • Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York
    • ,
  • Genovefa Anna Papanicolaou

      Affiliations

    • Department of Medicine, Service of Infectious Disease, Memorial Sloan-Kettering Cancer Center, New York, New York
    • Corresponding Author InformationCorrespondence and reprint requests to: Genovefa A. Papanicolaou, MD, Department of Medicine, Infectious Disease Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, Box, 9, New York, NY 10021.

Received 16 September 2008 ,Accepted 17 April 2009.

References 

  1. Almyroudis NG, Fuller A, Jakubowski A, et al. Pre- and post-engraftment bloodstream infection rates and associated mortality in allogeneic hematopoietic stem cell transplant recipients. Transpl Infect Dis. 2005;7:11–17
  2. Poltorak A, He X, Smirnova I, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science. 1998;282:2085–2088
  3. Arbour NC, Lorenz E, Schutte BC, et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet. 2000;25:187–191
  4. White SN, Taylor KH, Abbey CA, Gill CA, Womack JE. Haplotype variation in bovine Toll-like receptor 4 and computational prediction of a positively selected ligand-binding domain. Proc Natl Acad Sci USA. 2003;100:10364–10369
  5. Lorenz E, Mira JP, Frees KL, Schwartz DA. Relevance of mutations in the TLR4 receptor in patients with Gram-negative septic shock. Arch Intern Med. 2002;162:1028–1032
  6. Lorenz E, Frees KL, Schwartz DA. Determination of the TLR4 genotype using allele-specific PCR. BioTechniques. 2001;31:22–24
  7. Torok HP, Glas J, Tonenchi L, Mussack T, Folwaczny C. Polymorphisms of the lipopolysaccharide-signaling complex in inflammatory bowel disease: association of a mutation in the Toll-like receptor 4 gene with ulcerative colitis. Clin Immunol. 2004;112:85–91
  8. Radstake TR, Franke B, Hanssen S, et al. The Toll-like receptor 4 Asp299Gly functional variant is associated with decreased rheumatoid arthritis disease susceptibility but does not influence disease severity and/or outcome. Arthritis Rheum. 2004;50:999–1001
  9. Kiechl S, Lorenz E, Reindl M, et al. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med. 2002;347:185–192
  10. FineJp GR. A proportional hazards model for the sub-distribution of a competing risk. J Am Stat Assoc. 1999;94:496–509
  11. Mullally A, Ritz J. Beyond HLA: the significance of genomic variation for allogeneic hematopoietic stem cell transplantation. Blood. 2007;109:1355–1362
  12. Gereda JE, Klinnert MD, Price MR, Leung DY, Liu AH. Metropolitan home living conditions associated with indoor endotoxin levels. J Allergy Clin Immunol. 2001;107:790–796
  13. Alexander C, Rietschel ET. Bacterial lipopolysaccharides and innate immunity. J Endotoxin Res. 2001;7:167–202
  14. Lorenz E, Schwartz DA, Martin PJ, et al. Association of TLR4 mutations and the risk for acute GVHD after HLA-matched-sibling hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2001;7:384–387
  15. Schoenfeld DA. Sample-size formula for the proportional-hazards regression model. Biometrics. 1983;39:499–503

 Present address: FIRC Institute of Molecular Oncology, Milan, Italy.

 Financial disclosure: See Acknowledgments on page 1133.

PII: S1083-8791(09)00212-2

doi: 10.1016/j.bbmt.2009.04.012

Biology of Blood and Marrow Transplantation
Volume 15, Issue 9 , Pages 1130-1133 , September 2009

Article Tools